Nutra Pharma Reports Q1 2024 Net Loss of $426,934, Revenue Decline Due to Related Party Sales

Nutra Pharma Corp, along with its subsidiary ReceptoPharm, reported a net loss of $426,934 for the first quarter of 2024, a decrease from a net loss of $592,560 in the same period of the previous year. The company's net sales for the quarter were $37,732, down from $54,522 in the first quarter of 2023. This decline in revenue is attributed primarily to a significant reduction in sales to a related party, Avini Health, which accounted for approximately 48% of total revenues in the current quarter, compared to 65% in the prior year. The cost of sales also decreased to $22,484 from $51,925, contributing to a gross profit of $35,197, down from $103,099 year-over-year.

Operating expenses for Nutra Pharma decreased to $330,506 from $396,320 in the first quarter of 2023, reflecting a reduction in selling, general, and administrative costs. The company reported a loss from operations of $295,309, an improvement from the loss of $398,686 in the prior year. Other expenses, including interest and changes in the fair value of convertible notes, totaled $131,625, down from $193,874 in the previous year. The overall financial performance indicates a strategic effort to reduce costs while navigating a challenging revenue environment.

In terms of operational developments, Nutra Pharma's total assets decreased to $620,745 as of March 31, 2024, from $640,397 at the end of 2023. The company reported a working capital deficit of $14,278,846 and a stockholders' deficit of $14,191,742. The total liabilities increased to $14,812,487 from $14,408,705, primarily due to rising accounts payable and accrued expenses. The company continues to face liquidity challenges, as it does not have sufficient cash to sustain operations for the next twelve months without additional financing.

Nutra Pharma's strategic focus remains on securing additional funding to support its operations and growth plans. The company is currently exploring various financing options, including debt and equity, to address its financial needs. However, the ongoing reliance on external funding raises concerns about the company's ability to achieve profitable operations and repay its obligations. The management has expressed uncertainty regarding the availability of additional financing and the potential impact of market conditions on its business.

Looking ahead, Nutra Pharma's ability to continue as a going concern is contingent upon its success in increasing revenues and securing adequate financing. The company acknowledges the competitive environment in which it operates and the challenges associated with expanding its market share. As it navigates these complexities, Nutra Pharma remains committed to its product development initiatives and aims to enhance its operational efficiency to improve financial performance in the future.